Session » Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous
-
Abstract Number: 1411
Long-Term Safety of Different Doses of Canakinumab (<2, 2–<4, and 4–<8 mg/kg) in Patients Aged <4–≥65 Years: Results from the β-Confident Registry
-
Abstract Number: 1412
A Systematic Literature Review of Efficacy and Safety of Current Therapies for the Treatment of Hyperimmunoglobulinemia D Syndrome and TNF Receptor-Associated Periodic Syndrome
-
Abstract Number: 1413
Safety of Tocilizumab in Patients Aged <2 Years with Active Systemic Juvenile Idiopathic Arthritis Treated for One Year
-
Abstract Number: 1414
Pharmacovigilance of Biologics for Systemic Juvenile Idiopathic Arthritis Patients By the German Biologics Registry
-
Abstract Number: 1415
Emapalumab, an Anti-Interferon Gamma Monoclonal Antibody in Two Patients with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)
-
Abstract Number: 1416
Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
-
Abstract Number: 1417
Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes
-
Abstract Number: 1418
External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab
-
Abstract Number: 1419
Long-Term Outcome of 50 Patients with Linear Scleroderma Treated with Methotrexate
-
Abstract Number: 1420
Prospective Validation of Cone Beam Computed Tomography for the Assessment of Disease Progression in Linear Scleroderma of the Face
-
Abstract Number: 1421
Evaluating the Validity of SIX-Minute Walk Test in Juvenile Systemic Sclerosis
-
Abstract Number: 1422
Impact of Juvenile Localized Scleroderma on Longitudinal Quality of Life
-
Abstract Number: 1423
Autoantibody Testing in Pediatric Localized Scleroderma (LS)
-
Abstract Number: 1424
After 24 Months Observation Period the Patients Related Outcomes Improve Significantly in the Juvenile Scleroderma Inceptions Cohorte
-
Abstract Number: 1425
Update from the Juvenile Scleroderma Inception Cohort
-
Abstract Number: 1426
The Utilization of S100 Proteins Testing in Pediatric Rheumatology Patients in a Tertiary Care Institution and Implications for Care
-
Abstract Number: 1427
A New Model of Care for Pediatric Rheumatology in Ontario: Preliminary Results from Pilot Telemedicine Clinics Utilizing Advanced Clinician Practitioners in Arthritis Care
-
Abstract Number: 1428
Parental Involvement and Adolescents/Young Adults Self-Management during the Transition Period: A Cross-Sectional Survey in Childhood Onset Rheumatic Diseases
-
Abstract Number: 1429
A Quality Update: Improved Transfer Time Among Rheumatology Patients Transferring from Pediatric to Adult Care at an Academic Medical Center
-
Abstract Number: 1430
Research Priorities for Addressing Mental Health Needs of Pediatric Patients with Rheumatologic Disease
-
Abstract Number: 1431
Kikuchi-Fujimoto Disease: A Retrospective Analysis of 23 Pediatric Cases from a US Center
-
Abstract Number: 1432
Engaging Patients and Parents to Improve Mental Health for Youth with Rheumatologic Disease
-
Abstract Number: 1433
The Role of Patient and Parental Resilience in Amplified Musculoskeletal Pain Syndrome
-
Abstract Number: 1434
Patient-Proxy Agreement on Health-Related Quality of Life in Juvenile Fibromyalgia Syndrome
-
Abstract Number: 1435
Hormonal Contraception Use and Capacity to Self-Screen for Contraindications Among Adolescents in a Pediatric Rheumatology Clinic
-
Abstract Number: 1436
Pregnancy Outcomes in Partners of DMARD Exposed Men with Juvenile Idiopathic Arthritis – an Observational Study
-
Abstract Number: 1437
Use,Safety and Efficacy of Thalidomide from a Tertiary Level Pediatric Rheumatology Centre in India
-
Abstract Number: 1438
Treatment and Response of Down Syndrome Arthropathy